VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Short Interest Up 88.9% in December

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) saw a large increase in short interest in the month of December. As of December 31st, there was short interest totaling 3,385,220 shares, an increase of 88.9% from the December 15th total of 1,791,894 shares. Based on an average daily volume of 10,198,793 shares, the short-interest ratio is presently 0.3 days. Currently, 8.8% of the company’s shares are sold short. Currently, 8.8% of the company’s shares are sold short. Based on an average daily volume of 10,198,793 shares, the short-interest ratio is presently 0.3 days.

VistaGen Therapeutics Stock Performance

VistaGen Therapeutics stock traded up $0.00 during mid-day trading on Friday, reaching $0.67. The company’s stock had a trading volume of 348,428 shares, compared to its average volume of 1,453,834. The business’s 50 day simple moving average is $2.72 and its 200 day simple moving average is $3.07. VistaGen Therapeutics has a 12 month low of $0.63 and a 12 month high of $5.14. The company has a market capitalization of $26.62 million, a price-to-earnings ratio of -0.35 and a beta of 0.31.

VistaGen Therapeutics (NASDAQ:VTGN) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.03). The business had revenue of $0.26 million during the quarter, compared to analyst estimates of $0.16 million. As a group, sell-side analysts expect that VistaGen Therapeutics will post -1.77 EPS for the current year.

Institutional Trading of VistaGen Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of VTGN. Stempoint Capital LP lifted its stake in shares of VistaGen Therapeutics by 2.0% in the 2nd quarter. Stempoint Capital LP now owns 2,413,254 shares of the company’s stock valued at $4,827,000 after purchasing an additional 46,700 shares during the period. Two Sigma Investments LP lifted its holdings in shares of VistaGen Therapeutics by 223.5% during the third quarter. Two Sigma Investments LP now owns 289,409 shares of the company’s stock valued at $1,027,000 after purchasing an additional 199,958 shares in the last quarter. AdvisorShares Investments LLC grew its stake in shares of VistaGen Therapeutics by 1.9% in the third quarter. AdvisorShares Investments LLC now owns 206,998 shares of the company’s stock worth $735,000 after acquiring an additional 3,884 shares during the period. Boothbay Fund Management LLC raised its stake in VistaGen Therapeutics by 10.8% during the 3rd quarter. Boothbay Fund Management LLC now owns 197,024 shares of the company’s stock valued at $699,000 after buying an additional 19,166 shares during the last quarter. Finally, Jane Street Group LLC purchased a new position in VistaGen Therapeutics in the second quarter worth about $190,000. 78.39% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of VistaGen Therapeutics in a research note on Wednesday, October 8th. Maxim Group restated a “hold” rating on shares of VistaGen Therapeutics in a report on Wednesday, December 17th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $0.90 price target (down from $15.00) on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th. Stifel Nicolaus downgraded shares of VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $1.00 price target on the stock. in a research report on Wednesday, December 17th. Finally, William Blair restated a “market perform” rating on shares of VistaGen Therapeutics in a report on Wednesday, December 17th. Four equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and a consensus target price of $0.95.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.